Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commerce Committee opens Vioxx investigation

Executive Summary

House Energy & Commerce Committee officially opens investigation of Vioxx withdrawal with Nov. 23 letters to FDA and Merck. Committee Chair Joe Barton (R-Texas) and Ranking Member John Dingell (D-Mich.) ask FDA and Merck to submit records and internal communications including those related to safety reviews of Vioxx, the 2002 labeling change, advisory committee discussion of the drug and reviews of the 2000 VIGOR study data. The letter to Merck questions promotions for the drug and requests details on recommendations of the data safety monitoring committees of the VIGOR and APPROVe trials. The Senate Finance Committee held a hearing on Vioxx Nov. 18 (1"The Pink Sheet" Nov. 22, 2004, p. 3)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS045026

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel